NCT06019767

Brief Summary

The purpose of the research is to learn more about how to treat PTSD for people directly impacted by incarceration (i.e., have spent time in prison or jail). This research will help identify if a PTSD treatment group that is used in community settings, and led by individuals with lived experience, is helpful in reducing PTSD symptoms among people who have been directly impacted by incarceration. Participants will complete an interview to determine whether they are experiencing PTSD, and if so, will participate in a 6-week therapy group treatment.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
59

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Nov 2023

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 25, 2023

Completed
6 days until next milestone

First Posted

Study publicly available on registry

August 31, 2023

Completed
3 months until next milestone

Study Start

First participant enrolled

November 14, 2023

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 12, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 12, 2025

Completed
Last Updated

December 26, 2025

Status Verified

December 1, 2025

Enrollment Period

2.1 years

First QC Date

August 25, 2023

Last Update Submit

December 18, 2025

Conditions

Keywords

Previously incarceratedGroup therapyCognitive Processing Therapy

Outcome Measures

Primary Outcomes (10)

  • Feasibility: Participation

    Will be measured as the percentage of invited, eligible individuals who elect to participate.

    Study duration (up to 2 years)

  • Feasibility: Rate of retention

    Will be measured by percentage of participants who complete at least 9 of the 12 study sessions

    Study duration (up to 2 years)

  • Feasibility: Compliance through participation

    Will be measured by percentage of participants performing intervention activities during session, such as contributing to the discussion.

    Study duration (up to 2 years)

  • Feasibility: Compliance through homework

    Will be measured by percentage of participants completing homework assignments each week.

    Study duration (up to 2 years)

  • Feasibility: Compliance through completing assessments

    Will be measured by percentage of participants completing the pre-, mid-, and post-intervention assessment batteries.

    Study duration (up to 2 years)

  • Ratings from 0-5 by clinical supervisors on therapist adherence to five session elements

    Higher ratings indicate better adherence to session elements. Assesses for therapist adherence to CPT guidelines as secondary measure of intervention efficacy.

    Study duration (up to 2 years)

  • Ratings 1-7 by clinical supervisors on quality of session elements delivered by therapist

    Higher ratings indicate higher-quality session element (scores 1-7; 1=not satisfactory, 4= satisfactory, 7=excellent) by the clinical supervisor. Assesses for therapist compliance as secondary measure of intervention efficacy.

    Study duration (up to 2 years)

  • Change in suicide and self-harm ideation

    Beck Depression Inventory-II (BDI-II), item 9. Participants will answer the item on a scale of 0-3, where a score of 2 or 3 indicates higher ideation.

    Baseline to end of follow-up (up to 4.5 months)

  • Participant satisfaction

    Using the 8 item Client Satisfaction Questionnaire (CSQ-8), participants will rate their satisfaction with their experience. Scale ranges from 1-4, with total potential scores of 8 to 32 with higher scores indicating greater satisfaction.

    One week post-treatment (up to 7 weeks)

  • Change in PTSD symptom severity

    Using the PTSD Checklist for DSM-5 (PCL-5), which is a 20-item self-report measure, symptoms of PTSD will be assessed. Participants will answer items on a scale of 0-4, where 0=Not at all and 4=Extremely. Higher scores indicate higher symptom severity.

    Baseline to end of follow-up (up to 4.5 months)

Secondary Outcomes (5)

  • Change in depression symptom severity

    Baseline to end of follow-up (up to 4.5 months)

  • Change in trauma related thoughts and beliefs

    Baseline to end of follow-up (up to 4.5 months)

  • Change in aspects of hopelessness

    Baseline to end of follow-up (up to 4.5 months)

  • Change in substance use

    Baseline to end of follow-up (up to 4.5 months)

  • Change in anxiety symptom severity

    Baseline to end of follow-up (up to 4.5 months)

Study Arms (1)

Cognitive Processing Therapy (CPT)

EXPERIMENTAL

Groups of 6-8 receive CPT to treat PTSD

Behavioral: Cognitive Processing Therapy

Interventions

CPT is a type of cognitive behavioral therapy recommended for the treatment of PTSD. Delivered over 12 sessions with an emphasis on addressing trauma-related cognitions and challenging trauma-related beliefs. Includes homework assignments. For this study, CPT will be conducted in groups.

Cognitive Processing Therapy (CPT)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • years of age or older
  • completed a prison or jail sentence
  • no current psychosis symptoms
  • no active self-harm or active suicidal intent
  • able and willing to participate in group therapy
  • meet criteria for PTSD treatment need

You may not qualify if:

  • current and active psychosis
  • current and active self-harm and suicidality
  • no PTSD diagnosis
  • current substance use dependence (not including those used as prescribed for medical reasons) on alcohol, cocaine, amphetamines, inhalants, sedatives or sleeping pills, hallucinogens, or opioids

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Wisconsin

Madison, Wisconsin, 53705, United States

Location

MeSH Terms

Conditions

Stress Disorders, Post-Traumatic

Condition Hierarchy (Ancestors)

Stress Disorders, TraumaticTrauma and Stressor Related DisordersMental Disorders

Study Officials

  • Michael Koenigs, PhD

    University of Wisconsin, Madison

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 25, 2023

First Posted

August 31, 2023

Study Start

November 14, 2023

Primary Completion

December 12, 2025

Study Completion

December 12, 2025

Last Updated

December 26, 2025

Record last verified: 2025-12

Data Sharing

IPD Sharing
Will not share

Locations